China Pharma Holdings Inc Dossier
Qualitative Analysis
Business overview
China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty pharmaceutical company engaged in the development, manufacture, and marketing of generic and branded pharmaceutical, biochemical, and comprehensive healthcare products for human use in the People's Republic of China. Founded in 1999 and headquartered in Haikou, Hainan Province, the company operates primarily through its wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd.. China Pharma's product portfolio targets high-incidence and high-mortality diseases prevalent in China, including cardiovascular, central nervous system (CNS), infectious, and digestive diseases. Its dosage forms span dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. In addition to pharmaceuticals, the company has expanded into medical devices (such as therapeutic instruments for Dry Eye Disease) and protective health products (including N95 medical masks).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing the Consistency Evaluation of Generic Drugs required by Chinese regulatory authorities to qualify key products for large-scale government centralized procurement.
Expected impact: Enables the company's generic products to participate in national centralized procurement programs, potentially stabilizing sales volumes.
Shifting the product roadmap toward specialized medical devices and protective health products, highlighted by the acquisition and planned launch of the Dry Eye Disease Therapeutic Device.
Expected impact: Establishes a presence in a rapidly expanding therapeutic market to offset negative gross margins in the core generic drug portfolio.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of the invention patent and related preparation methods for Prinsepia Utilis Esterol sublingual tablets to expand the company's specialized drug pipeline.
Financial impact: Settled via the planned issuance of 12,600,000 restricted shares of common stock at $0.55 per share, preserving cash while diluting equity.
Acquisition of the invention patent covering Topiroxostat nanoemulsion and its preparation method to strengthen the company's intellectual property base in specialized drug delivery.
Financial impact: Settled via the issuance of 12,600,000 restricted shares of common stock at $0.70 per share.
Acquisition of the patent for Ipragliflozin tablets to strategically expand into the SGLT2 inhibitor market for treating type 2 diabetes.
Financial impact: Settled by issuing 7,000,000 restricted shares of common stock at a fixed price of $1.40 per share.